Guo Weina, Du Keye, Luo Shanshan, Hu Desheng
Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2022 May 4;12:861959. doi: 10.3389/fonc.2022.861959. eCollection 2022.
Lung cancer is characterized by the most common oncological disease and leading cause of cancer death worldwide, of which a group of subtypes known as non-small cell lung cancer (NSCLC) accounts for approximately 85%. In the past few decades, important progression in the therapies of NSCLC has enhanced our understanding of the biology and progression mechanisms of tumor. The application of immunotherapy and small molecule tyrosine kinase inhibitors has brought significant clinical benefits in certain patients. However, early metastasis and the emergence of resistance to antitumor therapy have resulted in the relatively low overall cure and survival rates for NSCLC. Autophagy is a conserved process that allows cells to recycle unused or damaged organelles and cellular components. It has been reported to be related to the progression of NSCLC and resistance to targeted therapy and cytotoxic chemotherapy. Therefore, autophagy is considered as a potential therapeutic target for NSCLC. Mounting results have been reported about the combination of tyrosine kinase inhibitors and inhibitors of autophagy in models of NSCLC. This review aims to provide a comprehensive review on the roles of autophagy in NSCLC, focusing on related clinical data of agents that regulate autophagy in NSCLC. Furthermore, this study will provide a theoretical basis for further improvement of autophagy-based cancer therapy.
肺癌是全球最常见的肿瘤疾病和癌症死亡的主要原因，其中一组被称为非小细胞肺癌（NSCLC）的亚型约占85%。在过去几十年中，NSCLC治疗方面的重要进展加深了我们对肿瘤生物学和进展机制的理解。免疫疗法和小分子酪氨酸激酶抑制剂的应用给某些患者带来了显著的临床益处。然而，早期转移和抗肿瘤治疗耐药性的出现导致NSCLC的总体治愈率和生存率相对较低。自噬是一个保守过程，它使细胞能够回收未使用或受损的细胞器和细胞成分。据报道，自噬与NSCLC的进展以及对靶向治疗和细胞毒性化疗的耐药性有关。因此，自噬被认为是NSCLC的一个潜在治疗靶点。在NSCLC模型中，关于酪氨酸激酶抑制剂与自噬抑制剂联合应用的结果不断涌现。本综述旨在全面回顾自噬在NSCLC中的作用，重点关注NSCLC中调节自噬的药物的相关临床数据。此外，本研究将为进一步改进基于自噬的癌症治疗提供理论依据。
